Results 51 to 60 of about 2,052,688 (283)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa, Katsuaki Imaizumi, Shinichi Makita, Kensei Tobinai   +3 more
core   +1 more source

Chimeric Antigen Receptor T Cell Therapy: A Review [PDF]

, 2018
Chimeric Antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). CARs are engineered and constructed specifically to reprogram a
Knouse, Michael
core   +1 more source

CD4+ chimeric antigen receptor T cells in for the long journey

, 2022
In a recently published article, Melenhorst et al. performed a longitudinal analysis on chimeric antigen receptor (CAR) T cells isolated from patients over 10 years after therapy, revealing expansion of a long-lived CD4+ CAR T-cell population with a ...
Beavis, PA, Chen, AXY, House, IG, Derrick, EB   +3 more
core   +1 more source

Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses

Advanced Science, EarlyView.
Dysregulated protein modifications drive tumorigenesis. RINES, an E3 ubiquitin ligase, represses tumor cell proliferation and metastasis by facilitating RING domain‐dependent, ubiquitin–proteasome‐mediated degradation of STAT3 and MYC, which consequently restrains cancer stemness and oncogenic progression.
Lili Li, Ka Man Ng, Xingsheng Shu, Xiaoxue Chai, Kai Yau Wong, Gopesh Srivastava, Anthony T.C. Chan, Wai Yee Chan, Qian Tao   +8 more
wiley   +1 more source

Advances in CAR-T therapy for central nervous system tumors

Biomarker Research
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue ...
Delian Zhou, Xiaojian Zhu, Yi Xiao
doaj   +1 more source

Chimeric Antigen Receptor-T Cell Therapy

HemaSphere, 2018
. Chimeric antigen receptor (CAR)-T cell therapy is a new class of cellular immunotherapies that involves ex vivo genetic modification of T cells to incorporate an engineered CAR.
Jochen Buechner, Marie José Kersten, Miriam Fuchs, Florence Salmon, Ulrich Jäger   +4 more
doaj   +1 more source

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

Signal Transduction and Targeted Therapy, 2023
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Yan Sun, Xiu-Na Yang, Shuang-Shuang Yang, Yi-Zhu Lyu, Bing Zhang, Kai-Wen Liu, Na Li, Jia-Chen Cui, Guang-Xiang Huang, Cheng-Lin Liu, Jie Xu, Jian-Qing Mi, Zhu Chen, Xiao-Hu Fan, Sai-Juan Chen, Shuo Chen   +15 more
doaj   +1 more source

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Zhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun   +5 more
doaj   +1 more source

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma [PDF]

, 2019
After unprecedented successes in B-cell malignancies, chimeric antigen receptor T cells have recently been investigated for the treatment of multiple myeloma.
Maguire, T., Lichtman, E., McKay, K., Sun, C., Ballard, B., Ramos, C., West, J., Dotti, G., Kale, B., Mahendravada, A., Savoldo, B., Tuchman, S.   +11 more
core   +1 more source

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

Advanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui, Yuening Sun, Ziyang Liu, Xuntao Lai, Yunshu Zhao, Yan'er Wang, Yuanming He, Fang Xu, Du Feng, Longlong Liu, Zhenqian Huang, Lijie Xing, Xinliang Mao   +12 more
wiley   +1 more source